Videos

An expert shares data from several clinical trials on the use of PARP inhibitors for maintenance therapies in ovarian cancer.

Dr Chirag A. Shah explains the front-line treatment options for ovarian cancer and the factors considered in choosing maintenance therapies.

A gynecologic oncologist discusses the importance of molecular testing in ovarian cancer and how it influences treatment selection.

Chirag A. Shah, MD, presents and reviews the case of a 59-year-old woman with ovarian cancer.

In this companion article, Dr. Lowell L. Hart shares key insights into how trilaciclib has begun to impact the management of chemotherapy-induced myelosuppression in patients with SCLC.

Cecelia H. Boardman, MD, John K. Chan, MD, and Thomas C. Krivak, MD, provide insight on dosing schedules for niraparib maintenance in advanced ovarian cancer.

Thomas C. Krivak, MD, leads a discussion on guideline recommendations regarding the use of PARP inhibitors in newly diagnosed advanced ovarian cancer.

Experts in gynecologic oncology review data and clinical implications for the use of PARP inhibitors from the GOG-0218, SOLO-1, PRIMA, and PAOLA-1 trials in advanced ovarian cancer.

A panel of experts share insight on patient factors to consider when selecting first-line maintenance therapy for advanced ovarian cancer.

John K. Chan, MD, leads a discussion on the role of first-line maintenance therapy for advanced ovarian cancer and the standard of care first-line maintenance approaches for a patient with gBRCA2-mutated disease.

Cecelia H. Boardman, MD, John K. Chan, MD, and Ashley Farione, PA-C, discuss their treatment approach to genetic testing in patients with advanced ovarian cancer.

Dr Thomas C. Krivak reviews a case of a 59-year-old woman who has stage IV, high-grade serous epithelial ovarian cancer and discusses ASCO and NCCN guideline recommendations for germline/somatic tumor testing.

Future opportunities being explored in clinical trials that show promise in treating advanced endometrial cancer.

What patients can expect in terms of prognosis when receiving systemic therapy for advanced endometrial cancer.

Recommendations on how to best prepare patients for chemotherapy, lenvatinib plus pembrolizumab, and other therapies used to treat advanced endometrial cancer.

Variables that impact choice of therapy for patients with advanced endometrial cancer.

The rationale for using systemic therapy to treat patients with advanced endometrial cancer.

A discussion on risk factors associated with endometrial cancer and the role of molecular testing to help evaluate for mismatch repair abnormality.

Dr Robert L. Coleman, US Oncology Research, reacts to how the case of a woman with advanced endometrial cancer was managed from diagnosis through treatment.

Dennis Scribner, Jr, MD, discusses the challenges for reaching patients who are at the greatest risk of developing cervical cancer.

Dan Petrylak, MD, discusses the pros and cons of using abiraterone as a front-line therapy for mCSPC and provides details of the PEACE-1 study.

Dr Petrylak presents our second case, a 62-year-old man with mCSPC.

An expert explains the unmet needs in the mCSPC landscape, as well as key takeaways if you are treating patients with this disease.

Dr Petrylak recalls the study design and results of the TITAN study.

Dan Petrylak, MD, presents our first case for discussion, an 80-year-old man with metastatic castration-sensitive prostate cancer (mCSPC). Front-line therapy options and monitoring for mCSPC are also mentioned.

Jeffrey Zonder, MD, discusses the safety results of a first-in-human trial of a bispecific monoclonal antibody in patients with relapsed/refractory multiple myeloma.

Afsaneh Barzi, Md, PhD, provides background on a new phase 1/2 studying exploring the combination of regorafenib and pembrolizumab in patients with refractory microsatellite stable colorectal cancer.

During the 2022 Gastrointestinal Cancers Symposium, Zev A. Wainberg, MD, predicts how gastric cancer treatment will look in the near future.

Megan May, PharmD, discusses fitting newer targeted therapies into the treatment paradigm for EGFR exon 20 insertion mutation-positive non–small cell lung cancer.

Danny Nguyen, MD, discusses an analysis of efficacy and adverse events of mobocertinib in patients with EGFR-positive non–small cell lung cancer that was presented at the European Society for Medical Oncology 2021 Congress.